title: Thrombin peptide TP508 accelerates closure of dermal excisions in animal tissue with surgically induced ischemia.
abstract: TP508 is a synthetic peptide corresponding to amino acids 508 through 530 of human prothrombin. We previously demonstrated that a single topical application of TP508 stimulates revascularization and healing of acute incisional and excisional wounds in normal, healthy rat skin. To determine if TP508 would enhance wound healing in ischemic skin, we used bipedicle flaps, cranially based flaps, and free grafts to surgically create ischemic regions on the backs of rats. Full-thickness, circular excisions were made within the flaps or grafts and immediately treated with a single application of saline +/- TP508 (0.1 microg/wound). Compared to wound closure in normal skin, ischemic skin wounds exhibited delayed closure, and the length of delay correlated with the degree of surgically induced ischemia. TP508 significantly accelerated closure in both normal and ischemic skin, resulting in closure rates that were increased within the first 7 days of wounding by 30% in normal tissue and bipedicle flaps, 50% in cranially based flaps, and 225% in free grafts. Moreover, in both flap models, TP508 restored the rate of closure to a rate approximating the control rate observed in normal skin. Histological comparisons of wound tissue from normal skin and cranially based flaps showed that ischemia reduced early recruitment of inflammatory cells at day 1 but increased inflammatory cell numbers in wound beds at day 14. TP508 treatment of ischemic flap wounds significantly increased early inflammatory cell recruitment and restored the normal rapid resolution of the inflammatory phase. In addition, at day 7, TP508-treated wounds appeared to have an increased number of large functional blood vessels compared to saline controls. These studies support the potential efficacy of TP508 in treating ischemic wounds in humans.
authors.affiliation: Department of Human Biological Chemistry and Genetics, The University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0645, USA.
authors.forename: A M
authors.initials: AM
authors.lastname: Norfleet
authors.forename: Y
authors.initials: Y
authors.lastname: Huang
authors.forename: L E
authors.initials: LE
authors.lastname: Sower
authors.forename: W R
authors.initials: WR
authors.lastname: Redin
authors.forename: R R
authors.initials: RR
authors.lastname: Fritz
authors.forename: D H
authors.initials: DH
authors.lastname: Carney
mesh_terms: D000818:Animals; D062109:Dermatologic Surgical Procedures; D004195:Disease Models, Animal; D005500:Follow-Up Studies; D007511:Ischemia / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D012680:Sensitivity and Specificity; D012867:Skin / Q000098:blood supply* / Q000187:drug effects*; D013524:Surgical Flaps; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology
chemical_list: D010446:Peptide Fragments; C076901:thrombin receptor-activating peptide (P508-530)